scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Acquired by Rubric Capital Management LP

Rubric Capital Management LP boosted its position in scPharmaceuticals Inc. (NASDAQ:SCPH) by 35.5% during the third quarter, Holdings Channel.com reports. The fund owned 4,775,000 shares of the company’s stock after purchasing an additional 1,250,000 shares during the quarter. Rubric Capital Management LP owned 0.10% of scPharmaceuticals worth $21,774,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SCPH. BNP Paribas Financial Markets grew its stake in scPharmaceuticals by 116.9% during the third quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock worth $26,000 after buying an additional 3,101 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in scPharmaceuticals in the third quarter valued at approximately $57,000. Virtu Financial LLC purchased a new stake in shares of scPharmaceuticals during the first quarter valued at approximately $90,000. Balanced Rock Investment Advisors LLC raised its stake in shares of scPharmaceuticals by 10.3% during the second quarter. Balanced Rock Investment Advisors LLC now owns 63,130 shares of the company’s stock valued at $275,000 after purchasing an additional 5,882 shares during the period. Finally, Assenagon Asset Management S.A. lifted its position in shares of scPharmaceuticals by 266.7% during the second quarter. Assenagon Asset Management S.A. now owns 72,692 shares of the company’s stock worth $316,000 after purchasing an additional 52,870 shares in the last quarter. 89.52% of the stock is currently owned by institutional investors and hedge funds.

scPharmaceuticals Price Performance

scPharmaceuticals stock opened at $3.60 on Wednesday. The company has a current ratio of 8.08, a quick ratio of 6.89 and a debt-to-equity ratio of 1.66. The stock has a 50 day moving average of $4.24 and a 200-day moving average of $4.43. scPharmaceuticals Inc. has a 52 week low of $3.08 and a 52 week high of $6.71.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on SCPH shares. Craig Hallum lowered their price target on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of scPharmaceuticals in a research report on Thursday, November 14th.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.